NeOncoFRAx is closely tied to Erasmus MC and can profit from its clinical expertise and translational research capacity. Through this collaboration, the company operates in a lean manner, allowing its funding to be used directly for research and development. The Erasmus MC team operates across the full spectrum of discovery, development, and patient care—all under one academic roof.
